Grimm W, Degenhardt M, Hoffman J, Menz V, Wirths A, Maisch B
Department of Medicine, Hospital of the Philipps-University of Marburg, Germany.
Eur Heart J. 1997 Sep;18(9):1465-9. doi: 10.1093/oxfordjournals.eurheartj.a015473.
Head-up tilt testing is widely used in the evaluation of patients with suspected neurally mediated syncope. Although it remains unclear which patients require medical therapy to prevent recurrent syncope, most centres initiate empiric medical therapy in all patients in whom neurally mediated syncope has been diagnosed. To determine the natural history of this condition, we followed 80 untreated patients.
All 80 study patients fulfilled the following inclusion criteria: (1) > or = 1 syncope in the upright position, (2) absence of structural heart disease, (3) unremarkable work-up for other known causes of syncope. Thirty-nine patients had a history of one episode of syncope (group A) and 41 > or = 2 episodes of syncope (group B). Head-up tilting was performed in all patients at 60 degrees for a maximum of 45 min without medical provocation ('Westminster Protocol').
Suspected neurally mediated syncope could be reproduced by tilt testing in four of 39 patients from group A vs 10 of 41 patients from group B (10% vs 24%, P = 0.1). Independent of the result of head-up tilt testing, all patients were prospectively followed without medical therapy. During 23 +/- 8 months follow-up, syncope recurred in four of 39 group A patients vs 22 of 41 group B patients (10% vs 54%, P < 0.05). The incidence of syncope during follow-up was not significantly different between patients with and without positive baseline tilt test (43% vs 30%, P = ns).
(1) 90% of patients with a single episode of syncope remain free of recurrent syncope without medical therapy irrespective of the result of tilt testing. (2) About half of patients with a history of > or = 2 syncopal episodes have recurrent syncope and, thus, may be appropriate candidates for prophylactic medical therapy. (3) Although head-up tilt testing at 60 degrees for up to 45 min does not appear to be useful to predict recurrent syncope in untreated patients, it is still a useful test in its evaluation.
头高位倾斜试验广泛应用于疑似神经介导性晕厥患者的评估。尽管尚不清楚哪些患者需要药物治疗以预防晕厥复发,但大多数中心对所有已诊断为神经介导性晕厥的患者都开始进行经验性药物治疗。为了确定这种疾病的自然病程,我们对80例未经治疗的患者进行了随访。
所有80例研究患者均符合以下纳入标准:(1)直立位晕厥≥1次;(2)无结构性心脏病;(3)排除其他已知晕厥原因的检查无异常。39例患者有1次晕厥病史(A组),41例患者有≥2次晕厥病史(B组)。所有患者均按照“威斯敏斯特方案”在60度进行头高位倾斜试验,最长45分钟,不使用药物激发。
A组39例患者中有4例、B组41例患者中有10例通过倾斜试验再现疑似神经介导性晕厥(10%对24%,P = 0.1)。无论头高位倾斜试验结果如何,所有患者均接受前瞻性随访且不进行药物治疗。在23±8个月的随访期间,A组39例患者中有4例晕厥复发,B组41例患者中有22例晕厥复发(10%对54%,P < 0.05)。基线倾斜试验阳性和阴性的患者随访期间晕厥发生率无显著差异(43%对30%,P = 无统计学意义)。
(1)90%单次晕厥发作的患者无论倾斜试验结果如何,未经药物治疗均无晕厥复发。(2)约一半有≥2次晕厥发作病史的患者有晕厥复发,因此可能适合预防性药物治疗。(3)尽管60度头高位倾斜试验长达45分钟似乎无助于预测未经治疗患者的晕厥复发,但在评估中仍是一项有用的检查。